retatrutide type 2 diabetes phase 2 results 2024 ada More data on dropped today at the conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Eli Lilly's retatrutide shows promising

Este impacto en el sistema nervioso central es un factor clave en su eficacia para controlar el peso

Although the renoprotective effects of SGLT-2 inhibitors are maintained at these eGFRs, the glucose-lowering effects of SGLT-2 inhibitors are significantly impaired at low eGFRs

The medication mimics a natural human glucagon-like peptide (GLP-1) to slow the passing of food through the stomach

Hoyme HE, Jones KL, Dixon SD, Jewett T, Hanson JW, Robinson LK, Msall ME, Allanson JE: Prenatal cocaine exposure and fetal vascular disruption

The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript